Sources

5 Total Sources

FDA Accepts Revolution Medicines' Daraxonrasib NDA for Metastatic Pancreatic Cancer After Phase 3 Trial

Simply Wall St2d ago

FDA Accepts Revolution Medicines' NDA for Daraxonrasib in Pancreatic Cancer

Cancer Network2d ago

FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer | CancerNetwork

dongascience.com2d ago

Revolution Medicines drug daraxonrasib doubles pancreatic cancer survival time - DongA Science

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | New England Journal of Medicine

Daraxonrasib hasn't received full FDA approval yet, but it carries an FDA Breakthrough Therapy designation and is available to qualifying patients at no cost through an expanded access program: https://www.wkyc.com/article/news/health/daily-dose-health ...